Posts

October 29, 2014

+
4:00 PM | Dopamine signaling leads to loss of polycomb repression and aberrant gene activation in experimental parkinsonism
Parkinson’s disease (PD) is the second most frequent neurodegenerative disease, affecting 1-2% of the population over 55 years of age. The main pathological feature of PD is the progressive death of neurons located in the midbrain that produce the neurotransmitter dopamine.  These neurons modulate the activity of a collection of ... The post Dopamine signaling leads to loss of polycomb repression and aberrant gene activation in experimental parkinsonism appeared first on EpiBeat.
+
1:46 PM | Video Tip of the Week: PaleoBioDB, for your paleobiology searches
Yeah, I know, it’s not genomics–but it’s the history of life on this planet–right?  The Paleobiology Database has been keeping records of this ancient biology for a while now, and they have some really nice tools to explore the fossil records and resources that have become available. It’s also interesting to me to see the […]

Varela S., González-Hernández J., Sgarbi L., Marshall C., Uhen M., Peters S. & McClennen M. (2014). paleobioDB: an R package for downloading, visualizing and processing data from the Paleobiology Database, Ecography, DOI: 10.1111/ecog.01154

Citation
+
1:01 PM | Automated Droplet Generator Saves Time and Improves Data Quality
Bio-Rad Laboratories announced the launch of its Automated Droplet Generator (AutoDG™ Instrument) for digital PCR. Combined with the QX200™ Droplet Reader and a laptop computer with QuantaSoft™ Software, the QX200™ AutoDG™ Droplet Digital™ PCR System provides a worry-free, automated way to generate droplets for high-quality data. “With a quick setup, you’re able to walk away […]
+
12:55 PM | Using cell circuits to program cellular outcomes
> One of my favourite things about the Till and McCulloch Meetings (#TMM2014) is the careful thought that goes into session organization. The balance of basic science, ethics, engineering, and industrial and clinical applications has always been a nice feature of the meeting. Having just listened to the speakers in the Systems, Synthetic & Applied Stem...Read more
+
11:55 AM | BMS taps F-star Alpha for immuno-oncology drug
Drug in development for breast and stomach cancers
+
11:29 AM | Sanofi board votes out CEO Viehbacher
Unanimous decision ends weeks of speculation
+
11:19 AM | 117,000 hepatitis C patients receive Sovaldi so far
Breakthrough drug has made $8.5bn for Gilead this year
+
10:28 AM | Charity demands action on cancer drug prices in UK
Breakthrough Breast Cancer wants commitment from all political parties
+
4:44 AM | Questions arise about upcoming “Factor GMO” study
Last week, Henry Rowlands at Sustainable Pulse announced the upcoming launch of a study on genetically engineered crops, which was later picked up by GM Watch. At a staggering $25 million budget, it promises to be “the largest and most…Read more ›
+
1:34 AM | Journal Watch: Foundation Medicine edition
Recent strength in $FMI shares comes in part from updated National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer (NSCLC) which includes the following statement:"The NCCN NSCLC Guidelines Panel strongly endorses broader molecular profiling with the goal of identifying rare driver mutations for which effective drugs may already be available, or to appropriately counsel patients regarding the availability of clinical trials. Broad molecular profiling is a […]
+
12:15 AM | Karus names two division heads
Simon Roitt and Peter Finan strengthen research team

October 28, 2014

+
3:50 PM | US judge cuts billions from Takeda/Lilly Actos payment
Court rules that companies must now pay damages of $36.8m rather than $9bn
+
3:34 PM | It’s Too Late to Apoptize
Tweet This Post
+
2:48 PM | GSE: ecco le tabelle per il calcolo dei nuovi incentivi rimodulati dal 2015
Il GSE, ente erogatore degli incentivi per il fotovoltaico, ha pubblicato le tabelle per il calcolo della rimodulazione dei contributi per i grandi impianti fotovoltaici esistenti, ai sensi del Decreto del Ministero dello Sviluppo Economico del 17 ottobre 2014, in…Read more →
+
12:04 PM | How relationships and collaboration breed scientific breakthroughs
> Last month, Signals re-posted a blog entry of mine from The Black Hole where I lamented the lack of teamwork in the life sciences. There are, however, always exceptions and I want to highlight one such exception that took the field of blood stem cell expansion by storm last month. It was also presented...Read more
+
11:55 AM | Valeant dangles higher bid in front of Allergan shareholders
Proposes $200 a share deal
+
11:04 AM | Controversial pancreatic cancer campaign wins award
Team Darwin wins gold at 2014 IPA Effectiveness Awards
+
10:08 AM | EU consortium focuses on antibiotic 'husbandry'
IMI-backed group to research ways to tackle antimicrobial resistance
+
8:52 AM | Eisai backs competition to find star of epilepsy comic book
Teams up with Medikidz to educate young people about the condition
+
5:22 AM | Nanoscientists Among Us… as Science Communicators
“The communication of scientific findings with lay audiences has taken on heightened importance in recent years and scientists are now frequently being asked to play the role of public communicator for their work.” – Michael A. Cacciatore In a recent letter in Nature Nanotechnology, Anthony Dudo and colleagues survey nanoscientists as public science communicators. I can especially appreciate their results, because I used to be a nanoscientist myself! That was my past […]
+
12:16 AM | The pharma business environment in the US
Tighter regulations, more pricing controls and increased international competition will drive market improvements
+
12:15 AM | Biogen Idec appoints senior neuroscientists
Christopher Henderson and Richard Ransohoff make the move from academia
+
12:15 AM | New head of strategy for Saatchi & Saatchi Health
Alix Critchley joins from Serco

October 27, 2014

+
10:10 PM | How vaccine deniers abuse the appeal to authority
Updated 27 October 2014. See another article about the Argument from Authority logical fallacy and Peter Doshi.   Science is built upon the scientific method, which is a logical process of observation, experiment, analysis, and publication. It is simple, but it requires work. Over time, after numerous experiments, nearly always published in peer-reviewed journals, followed by frequent […]Continue reading «How vaccine deniers abuse the appeal to authority»
+
9:58 PM | The zombie anti-vaccine lie–Peter Doshi and the appeal to authority
A few  months ago, I wrote an article about Peter Doshi, a Ph.D. who is doing some postdoctoral work at Johns Hopkins University, one of the leading institutions of higher learning in the USA. Doshi is truly not very notable in science, except last year, he wrote an article about flu vaccines, basically employing the Nirvana Fallacy […]Continue reading «The zombie anti-vaccine lie–Peter Doshi and the appeal to authority»
+
8:32 PM | How Does Synaptic Transmission Happen So Fast?
While neurons rapidly propagate information in their interior via electrical signals, they communicate with each other at special contact points known as the synapses. Chemical messenger substances, the neurotransmitters, are stored in vesicles at the synapses. When a synapse becomes active, some of these vesicles fuse with the cell membrane and release their contents. To […]
+
6:48 PM | Two Stem Cell Beliefs Debunked
Two recent papers may have upturned two common beliefs about adult stem cells. The esophagusRead more about Two Stem Cell Beliefs DebunkedComments
+
3:04 PM | Genome Editing and Reporter Technologies Enable Endogenous Pathway High-Throughput Assays
This article review was written by guest author, Amy Landreman, in the Cellular Analysis and Proteomics Group at Promega. Charcot-Marie Tooth (CMT) disease is one of the most common inherited neurological disorders affecting approximately 2.8 million people worldwide. The most common form of CMT, CMT Type 1A, is caused by a 1.5Mb genomic duplication on […]
+
2:27 PM | EFPIA promotes pharma's contribution to Europe
Launches Pharmafigures website to detail industry investment
+
12:22 PM | Merck & Co's cancer drug Keytruda gaining traction in US
Anti-PD-1 drug is used in around three quarters of eligible patients in US just weeks after FDA approval
45678910
290 Results